1887

Abstract

The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a surveillance study established in 2004 to monitor the activity of tigecycline, the first glycylcycline, and comparator agents [-lactams (including penicillins, cephalosporins and carbapenems), glycopeptides, tetracyclines, fluoroquinolones and oxazolidinones] against Gram-positive and Gram-negative pathogens worldwide. This report examines 1692 isolates of collected in the continental United States between January 2004 and September 2005. Meticillin-resistant (MRSA) accounted for 52.0 % of isolates. Prevalence of MRSA by state ranged from 12.5 % in New Hampshire to 100 % in Kentucky. All isolates were susceptible to tigecycline, linezolid and vancomycin. , tigecycline was potent against both meticillin-susceptible (MSSA) (MIC and MIC=0.12 μg ml) and MRSA (MIC=0.12 μg ml; MIC=0.25 μg ml). Only a single isolate was resistant to three or more antimicrobial classes. Ninety-six isolates (5.7 %) were susceptible to the complete antimicrobial panel.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46710-0
2007-09-01
2021-03-08
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/9/1189.html?itemId=/content/journal/jmm/10.1099/jmm.0.46710-0&mimeType=html&fmt=ahah

References

  1. Anderegg T. R., Sader H. S., Fritsche T. R., Ross J. E., Jones R. N. 2005; Trends in linezolid susceptibility patterns: report from the 2002–2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. . Int J Antimicrob Agents 26:13–21 [CrossRef]
    [Google Scholar]
  2. Babinchak T., Ellis-Grosse E., Dartois N., Rose G. M., Loh E. 2005; The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. The Tigecycline 301 and 306 Study Groups. Clin Infect Dis 41:S354–S367 [CrossRef]
    [Google Scholar]
  3. Bergeron J., Ammirati M., Danley D., James L., Norcia M., Retsema J., Strick C. A., Su W.-G., Sutcliffe J., Wondrack L. 1996; Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 40:2226–2228
    [Google Scholar]
  4. Bouchillon S. K., Hoban D. J., Johnson B. M., Johnson J. L., Hsiung A., Dowzicky M. J. 2005; In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (T.E.S.T. Program; 2004). Diagn Microbiol Infect Dis 52:173–179 [CrossRef]
    [Google Scholar]
  5. Boyce J. M. 2005; Meticillin-resistant Staphylococcus aureus : USA. Lancet Infect Dis 5:653–654 [CrossRef]
    [Google Scholar]
  6. Bozdogan B., Esel D., Whitener C., Browne F. A., Appelbaum P. C. 2003; Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 52:864–868 [CrossRef]
    [Google Scholar]
  7. Bradford P. A., Weaver-Sands D. T., Petersen P. J. 2005; In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 41:S315–S332 [CrossRef]
    [Google Scholar]
  8. Chang S., Sievert D. M., Hageman J. C., Boulton M. L., Tenover F. C., Downes F. P., Shah S., Rudrik J. T., Pupp G. R. other authors 2003; Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348:1342–1347 [CrossRef]
    [Google Scholar]
  9. Chen C.-J., Huang Y.-C. 2005; Community-acquired methicillin-resistant Staphylococcus aureus in Taiwan. J Microbiol Immunol Infect 38:376–382
    [Google Scholar]
  10. CLSI 2005 Performance standard for antimicrobial susceptibility testing , document M100-S15 Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  11. Cosgrove S. E., Sakoulas G., Perencevich E. N., Schwaber M. J., Karchmer A. W., Carmeli Y. 2003; Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53–59 [CrossRef]
    [Google Scholar]
  12. Cunha B. A. 2005; Methicillin-resistant Staphylococcus aureus : clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11 (Suppl. 4):33–42
    [Google Scholar]
  13. Daum R. S., Ito T., Hiramatsu K., Hussain F., Mongkolrattanothai K., Jamklang M., Boyle-Vavra S. 2002; A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 186:1344–1347 [CrossRef]
    [Google Scholar]
  14. Ellis-Grosse E. J., Babinchak T., Dartois N., Rose G., Loh E. 2005; The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. The Tigecycline 300 and 305 cSSSI Study Groups. Clin Infect Dis 41:S341–S353 [CrossRef]
    [Google Scholar]
  15. Engemann J. J., Carmeli Y., Cosgrove S. E., Fowler V. G., Bronstein M. Z., Trivette S. L., Briggs J. P., Sexton D. J., Kaye K. S. 2003; Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36:592–598 [CrossRef]
    [Google Scholar]
  16. Fritsche T. R., Jones R. N. 2004; Antimicrobial activity of tigecycline (GA-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 24:567–571 [CrossRef]
    [Google Scholar]
  17. Fritsche T. R., Kirby J. T., Jones R. N. 2004; In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 49:201–209 [CrossRef]
    [Google Scholar]
  18. Fritsche T. R., Sader H. S., Stilwell M. G., Dowzicky M. J., Jones R. N. 2005; Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004. Diagn Microbiol Infect Dis 52:195–201 [CrossRef]
    [Google Scholar]
  19. Gomes A. R., Vinga S., Zavolan M., de Lencastre H. 2005; Analysis of the genetic variability of virulence-related loci in epidemic clones of methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 49:366–379 [CrossRef]
    [Google Scholar]
  20. Graffunder E. M., Venezia R. A. 2002; Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 49:999–1005 [CrossRef]
    [Google Scholar]
  21. Haddadin A. S., Fappiano S. A., Lipsett P. A. 2002; Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 78:385–392 [CrossRef]
    [Google Scholar]
  22. Hoban D. J., Bouchillon S. K., Johnson B. M., Johnson J. L., Dowzicky M. J. 2005; In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (T.E.S.T. Program, 2004). Diagn Microbiol Infect Dis 52:215–227 [CrossRef]
    [Google Scholar]
  23. Katayama Y., Ito T., Hiramatsu K. 2000; A new class of genetic element, staphylococcus cassette chromosome mec , encodes methicillin resistance in Staphylococcus aureus . Antimicrob Agents Chemother 44:1549–1555 [CrossRef]
    [Google Scholar]
  24. Koeth L. M., Miller L. A. 2005; Evolving concepts of pharmaceutical company-sponsored surveillance studies. Clin Infect Dis 41 (Suppl. 4):S279–S282 [CrossRef]
    [Google Scholar]
  25. McAleese F., Petersen P., Ruzin A., Dunman P. M., Murphy E., Projan S. J., Bradford P. A. 2005; A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 49:1865–1871 [CrossRef]
    [Google Scholar]
  26. Moran G. J., Amii R. N., Abrahamian F. M., Talan D. A. 2005; Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 11:928–930 [CrossRef]
    [Google Scholar]
  27. National Nosocomial Infections Surveillance System 2004; National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32:470–485 [CrossRef]
    [Google Scholar]
  28. NCCLS 2003 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , document M7-A6 Wayne, PA: National Committee for Clinical Laboratory Standards;
    [Google Scholar]
  29. Oliveira D. C., Milheiriço C., de Lencastre H. 2006; Redefining a structural variant of staphylococcal cassette chromosome mec , SCC mec type VI. Antimicrob Agents Chemother 50:3457–3459 [CrossRef]
    [Google Scholar]
  30. Padmanabhan R. A., Fraser T. G. 2005; The emergence of methicillin-resistant Staphylococcus aureus in the community. Cleve Clin J Med 72:235–241 [CrossRef]
    [Google Scholar]
  31. Peeters M. J., Sarria J. C. 2005; Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 330:102–104 [CrossRef]
    [Google Scholar]
  32. Salgado C. D., Farr B. M., Calfee D. P. 2003; Community-acquired methicillin-resistant Staphylococcus aureus : a meta-analysis of prevalence and risk factors. Clin Infect Dis 36:131–139 [CrossRef]
    [Google Scholar]
  33. Stemper M. E., Shukla S. K., Reed K. D. 2004; Emergence and spread of community-associated methicillin-resistant Staphylococcus aureus in rural Wisconsin; 1989 to 1999 J Clin Microbiol 42:5673–5680 [CrossRef]
    [Google Scholar]
  34. Stevenson K. B., Searle K., Stoddard G. J., Samore M. H. 2005; Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in rural communities, western United States. Emerg Infect Dis 11:895–903 [CrossRef]
    [Google Scholar]
  35. Weber J. T. 2005; Community-associated methicillin-resistant Staphylococcus aureus . Clin Infect Dis 41:S269–S272 [CrossRef]
    [Google Scholar]
  36. Wilson P., Andrews J. A., Charlesworth R., Walesby R., Singer M., Farrell D. J., Robbins M. 2003; Linezolid resistance in clinical isolates of Staphylococcus aureus . J Antimicrob Chemother 51:186–188 [CrossRef]
    [Google Scholar]
  37. Wyeth Pharmaceuticals 2005 Tygacil product insert Philadelphia: Wyeth Pharmaceuticals;
    [Google Scholar]
  38. Young L. S., Perdreau-Remington F., Winston L. G. 2004; Clinical, epidemiologic, and molecular evaluation of a clonal outbreak of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 38:1075–1083 [CrossRef]
    [Google Scholar]
  39. Zinner S. H. 2005; Overview of antibiotic use and resistance: setting the stage for tigecycline. Clin Infect Dis 41:S289–S292 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46710-0
Loading
/content/journal/jmm/10.1099/jmm.0.46710-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error